Literature DB >> 2987536

Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles.

C E Fricks, J P Icenogle, J M Hogle.   

Abstract

Treatment of the Sabin strain of type 1 poliovirus with trypsin produced two stable fragments of capsid protein VP1 which remained associated with the virions. Trypsinized virus was fully infectious and was neutralized by type-specific antisera. The susceptible site in the Sabin 1 strain was between the lysine at position 99 and the asparagine at position 100. A similar tryptic cleavage occurred in the Leon and Sabin strains of type 3 poliovirus, probably at the arginine at position 100, but not in the type 1 Mahoney strain, which lacks a basic residue at either position 99 or position 100. Tryptic treatment of heat-treated virus and 14S assembly intermediates produced unique stable fragments which were different from those produced in virions. The implications of our results for future characterization of the surface structures of these particles and structural rearrangements in the poliovirus capsid are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987536      PMCID: PMC254874     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Early stages of enterovirus infection.

Authors:  J J HOLLAND; B H HOYER
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1962

2.  Changes in three of the four coat proteins of oral polio vaccine strain derived from type 1 poliovirus.

Authors:  O M Kew; M A Pallansch; D R Omilianowski; R R Rueckert
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

3.  Morphogenesis of poliovirus. I. Association of the viral RNA with coat protein.

Authors:  M F Jacobson; D Baltimore
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

4.  Silver staining of proteins in polyacrylamide gels.

Authors:  W Wray; T Boulikas; V P Wray; R Hancock
Journal:  Anal Biochem       Date:  1981-11-15       Impact factor: 3.365

5.  A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.

Authors:  J Icenogle; S F Gilbert; J Grieves; J Anderegg; R Rueckert
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

6.  Preparation and characterization of encephalomyocarditis (EMC) virus.

Authors:  R R Rueckert; M A Pallansch
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

8.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

9.  A gas-liquid solid phase peptide and protein sequenator.

Authors:  R M Hewick; M W Hunkapiller; L E Hood; W J Dreyer
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

10.  Poliovirus morphogenesis. I. Identification of 80S dissociable particles and evidence for the artifactual production of procapsids.

Authors:  M E Marongiu; A Pani; M V Corrias; M Sau; P La Colla
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

View more
  30 in total

1.  Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus.

Authors:  D M Belnap; D J Filman; B L Trus; N Cheng; F P Booy; J F Conway; S Curry; C N Hiremath; S K Tsang; A C Steven; J M Hogle
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Authors:  Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Vaia Pliaka; Christine Kottaridi; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Dimitri Komiotis; Panayotis Markoulatos
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

6.  Antigenic modification of polioviruses by host proteolytic enzymes.

Authors:  M Roivainen; A Huovilainen; T Hovi
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.

Authors:  C E Fricks; J M Hogle
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

8.  Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions.

Authors:  L Piirainen; A Airaksinen; T Hovi; M Roivainen
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design.

Authors:  Ke Lyu; Guang-Chuan Wang; Ya-Ling He; Jian-Feng Han; Qing Ye; Cheng-Feng Qin; Rong Chen
Journal:  J Biol Chem       Date:  2014-12-09       Impact factor: 5.157

10.  Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.

Authors:  Sabine van der Sanden; Mark A Pallansch; Jan van de Kassteele; Nasr El-Sayed; Roland W Sutter; Marion Koopmans; Harrie van der Avoort
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.